Zero-Sales Biotechs May Damage Your Financial Health

, , , , , , , , , ,

China's biotech unicorns are chasing a big prize. Landing it may prove elusive. BeiGene Ltd. raised $903 million in a secondary listing in Hong Kong last week. The company’s market value has swelled to $9.4 billion since its 2016 initial public offering on the Nasdaq, despite the firm being at the “clinical stage”– a euphemism for having sales. Competitor […]

Read More...